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Received September 11, 2014; accepted April 10, 2015AbstractBackground: Chronic obstructive pulmonary disease (COPD) has been associated with increased oxidative stress or reduced antioxidant re-
sources. The main goal of this study was to evaluate the levels of serum ischemia-modified albumin (IMA), oxidized low-density lipoprotein (ox-
LDL), total oxidant status (TOS), and total antioxidant status in patients with stable COPD, compared with a control group.
Methods: This study was performed on 51 patients with stable COPD (42 men and 9 women; mean age 56.92 ± 3.0 years) and 45 healthy control
participants (32 men and 13 women; 54.8 ± 3.8 years). The levels of serum lipids, IMA, total antioxidant status, TOS, and ox-LDL were
measured in all participants.
Results: The levels of serum IMA, ox-LDL, and TOS were significantly higher in patients with COPD than those in control individuals. There
was no difference between the levels of serum total antioxidant status, triglycerides, total cholesterol, and low-density lipoprotein cholesterol
(LDL-C) of patients with COPD and those of control individuals. Serum high-density lipoprotein cholesterol levels were significantly lower in
patients with COPD than in control individuals.
Conclusion: Our study indicated that serum IMA, ox-LDL, and TOS may be increased as a result of chronic hypoxia, inflammation, and
oxidative stress in patients with severe and very severe stable COPD. Our findings also revealed that IMA is higher in patients with Global
Initiative for Chronic Obstructive Lung Disease Stages II, III, and IV, while TOS and ox-LDL are higher in patients with Global Initiative for
Chronic Obstructive Lung Disease Stage IV. Measurements of serum IMA, TOS, and ox-LDL levels may be useful markers in the evaluation of
stable COPD.
Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Chronic obstructive pulmonary disease (COPD) is a pre-
ventable and treatable disease characterized by generally
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1726-4901/Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Assthat is associated with an abnormal inflammatory response of
the lungs to noxious particles or gases.1,2
Oxidative stress is related to an imbalance between the
increased production of reactive oxygen species (ROS) and
reactive nitrogen species (RNS), and reduced antioxidant ca-
pacity.3,4 The pathogenesis in COPD includes disturbed oxi-
danteantioxidant and proteinaseeantiproteinase balances.5
Lungs are continuously subject to oxidants, arising either
endogenously by metabolic reactions (e.g., from mitochon-
drial electron transport during respiration or activation of
phagocytes) or exogenously from air pollutants or cigaretteociation. All rights reserved.
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acterized by the activation of inflammatory cells, including
neutrophils, alveolar macrophages, monocytes, and epithelial
and endothelial cells, releasing ROS and RNS, which can in-
crease inflammation and tissue damage.2,7 It has been
observed that ROS may damage proteins, DNA, and lipids,
and may cause lung injuries.1 Furthermore, ROS and RNS can
act on proteins to cause nitration and oxidation of peptides,
bond cleavage, or amino acid side chain modifications. The
levels of nitrated proteins (fibrinogen, transferrin, plasmin-
ogen, and ceruloplasmin) are increased in smokers.3,6,7
The amino terminal end (N-terminal) of albumin molecules
is connected to transitional metals such as cobalt, copper, and
nickel.8 Under acute ischemic conditions, the N terminus of
albumin is changed, possibly as a result of hypoxia, acidosis,
or free-radical injury. The metal-binding capacity of albumin
is then reduced. Ischemia-modified albumin (IMA) is
increased in most patients with cardiac ischemia, liver
cirrhosis, acute infections, advanced cancers, brain ischemia
(stroke), and end-stage renal disease.9
Oxidized low-density lipoprotein (ox-LDL) is generated
during oxidative stress and increases the production of ROS.10
It accumulates in macrophages and other cell types at the site
of chronic inflammation.10,11 Additionally, ox-LDL can induce
atherosclerotic plaque formation and progression, matrix
degradation, endothelial cell apoptosis, and the secretion of
matrix metalloproteinases, mediating the degradation of pro-
tein components of the extracellular matrix and of basement
membranes in target cells.10,12
There exists an excessively abundant number of ROS rad-
icals, such as superoxide anion, hydroxyl, alkyl, alkoxyl,
peroxyl, and semiquinone radicals, and RNS radicals, such as
nitric oxide and nitrogen dioxide, which include phenols and
quinines. However, separately measuring different oxidant
species is time consuming, costly, and impractical, and
because their oxidant effects are additive, evaluation of total
oxidant status (TOS) is therefore more practical.13 In our
study, TOS was measured in relation to the cumulative
oxidative effects of various oxidants. Total antioxidant status
(TAS) was also measured to evaluate the efficiency of all
antioxidants, such as superoxide dismutase, glutathione
peroxidase, glutathione reductase, and catalase, as well as
nonenzyme antioxidant molecules including glutathione, uric
acid, melatonin, vitamins A, C, and E, ferritin, transferrin, and
ceruloplasmin.
The aim of our study was to evaluate pulmonary oxidative
stress parameters such as IMA, TOS, and ox-LDL in patients
with stable COPD and in a control group. However, more
recent studies have failed to find a significant relationship
between plasma oxidant and antioxidant capacities, and pul-
monary function in patients with COPD. To the best of our
knowledge, there are no studies evaluating the relationship
between serum IMA and COPD. The aim of our study was to
investigate whether IMA and ox-LDL levels are related to the
pathogenesis of COPD. IMA and ox-LDL levels were also
evaluated in patients and control groups in order to define the
level of pulmonary oxidative stress.2. Methods2.1. ParticipantsThis study was performed on 51 COPD patients (42 men
and 9 women), aged 35e75 years (mean 56.92 ± 3.0 years),
and 45 healthy control individuals (32 men and 13 women),
aged 35e75 years (mean 54.8 ± 3.8 years). Patients with
stable COPD who were admitted to the outpatient clinic of
Meram Medical School of Necmettin Erbakan University in
Konya, Turkey, between November 2012 and September 2013
were included in the study. A diagnosis of COPD was
established based on the medical history and spirometric data
[forced expiratory volume in 1 second (FEV1)/forced vital
capacity (FVC) ratio <0.7] of patients. All patients with
COPD had at least Global Initiative for Chronic Obstructive
Lung Disease (GOLD) Stages II, III, and IV of COPD.
Control individuals with normal spirometry and no infectious
or inflammatory diseases were matched with patients in terms
of age, sex, body mass index (BMI), and smoking history
(pack-years). Control individuals were volunteers recruited
from the hospital staff. Healthy control participants were fully
examined by a chest physician and excluded if they had lung
impairment, cardiovascular diseases, diabetes mellitus (DM)
or other diseases, or a history of use of any medicine and
vitamins for the prior 3 months.
Those with no exacerbations due to any reason in the prior
8 weeks; no changes in respiratory medication on a standard
treatment regimen consisting of inhaled corticosteroids, N-
acetylcysteine (NAC), and beta adrenergic agonists; and the
absence of infection were included in the study, who consti-
tuted the patient group. Patients with COPD were current
smokers or exsmokers with at least 10 pack-years. Those with
malignant disease, systemic inflammatory disease, chronic
gastrointestinal disease, another lung disease, hypertension,
cardiovascular disease, and COPD exacerbations, such as an
increase in cough, sputum production, and worsening of
dyspnea or sputum purulence within the prior 8 weeks, and
those treated with oral corticosteroids or any medication apart
from COPD maintenance therapy or immunosuppressors for
any reason within the prior 3 months were excluded. The
study was approved by the local ethics committee (no. 2012/
70). All participants were informed about the design, and
written consents were obtained.2.2. Body compositionBMI was calculated as weight divided by the square of the
height (kg/m2).2.3. Pulmonary function testingThe stages of COPD were determined using GOLD
criteria 201214: GOLD II (moderate), FEV1/FVC <70%,
FEV1 <80% and 50%; GOLD III (severe), FEV1/FVC
<70%, FEV1 <50% and 30%; and GOLD IV (very severe):
FEV1/FVC <70%, FEV1 <30%. FEV1, FVC, FEV1/FVC
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criteria. FEV1 was measured 20 minutes after the adminis-
tration of 400 mg of albuterol through a metered-dose inhaler.
Spirometry was performed using a Sensor Medics VMax 22
Respiratory Analyzer (SensorMedics Corporation, Yorba
Linda, CA, USA). According to the GOLD criteria,
the severity of COPD was as follows: 19 patients were in
GOLD Stage II, 17 in GOLD Stage III, and 15 in GOLD
Stage IV.2.4. Laboratory methodsBlood samples were obtained from stable-phase COPD
patients and healthy control participants. Fasting peripheral
blood was collected in empty vacuum tubes after overnight
fasting (8 hours) and serum samples were obtained after
suitable centrifugation. The samples were stored frozen at
¡80C until the day of analysis of serum IMA, TAS, TOS,
and ox-LDL levels. Thereafter, serum triglycerides, total
cholesterol (total-C), high-density lipoprotein cholesterol
(HDL-C), and low-density lipoprotein cholesterol (LDL-C)
levels were measured immediately.
Arterial oxygen and carbon dioxide tensions (pO2 and pCO2)
were analyzed using a blood gas analyzer. For arterial blood gas
analysis, blood was drawn from the brachial artery using a
dedicated preheparinized blood sampler, while the patients
were breathing room air, and studied with a blood gas analyzer
(ABL 700 series; Radiometer, Copenhagen, Denmark).2.5. Biochemical analyses
2.5.1. Measurement of TAS
We determined serum TAS level using an automated
measurement method based on the bleaching of the charac-
teristic color of a more stable 2,20-azino-bis(3-ethylbenz-
thiazoline 6-sulfonic acid) radical cation by antioxidants.15
The results were expressed in mmol Trolox equivalents/L.
2.5.2. Measurement of TOS
Serum TOS level was determined using a novel automated
measurement method.16 Oxidants present in the sample
oxidize the ferrous ion-o-dianisidine complex to ferric ion.
The oxidation reaction is enhanced by glycerol molecules,
abundantly present in the reaction medium. The ferric ion
makes a colored complex with xylenol orange in an acidic
medium. The color intensity, which can be measured spec-
trophotometrically, is related to the total amount of oxidant
molecules present in the sample. The assay is calibrated with
hydrogen peroxide, and the results are expressed in terms of
micromolar hydrogen peroxide (H2O2) equivalents per liter
(mmol H2O2 equiv./L).
2.5.3. Measurement of IMA levels
The IMA level was measured using a colorimetric assay
based on the measurement of unbound cobalt after incubation
with patients' serum, developed by Bar-Or et al.17 Increasedamounts of IMA result in reduced cobalt binding, conse-
quently increasing the levels of residual unbound cobalt
available for the formation of complexes with a chromogen
[dithiothreitol (DDT)], which can be measured photometri-
cally. The procedure was as follows: 50 mL of 0.1% cobalt
chloride was added to 200 mL of serum, gently mixed, and
held for 10 minutes for adequate cobaltealbumin binding.
Fifty microliters of DTT, at a concentration of 1.5 mg/mL, was
added as a colorizing agent, and the reaction was stopped 2
minutes later by adding 1.0 mL of 0.9% sodium chloride. The
colored product was measured at 470 nm, compared with a
serum-cobalt blank without DTT, and reported in absorbance
units.
In our study, adjusted IMA was calculated as follows: (in-
dividual serum albumin concentration/median serum albumin
concentration of the population)  IMA value in absorbance
units. This formula was applied to correct IMA values for
serum albumin, and the median serum albumin concentration
of each group was used separately.18
2.5.4. Measurement of ox-LDL levels
Analysis of ox-LDL was performed on serum samples
using the Mercodia ox-LDL enzyme-linked immunosorbent
assay kit (Mercodia AB, Uppsala, Sweden), in accordance
with the manufacturer's guidelines. Absorbance was measured
at 450 nm on an ELx800 Absorbance Microplate Reader
(BioTek Instruments, Inc., Winooski, VT, USA). This assay
employs a quantitative sandwich enzyme immunoassay tech-
nique that measures ox-LDL, with the resulting concentration
values reported in mU/L.
2.5.5. Measurement of albumin, triglyceride, total-C, HDL-
C, and LDL-C levels
Serum albumin, triglycerides, total-C, HDL-C, and LDL-C
levels were measured using commercially available kits, based
on routine methods, on the Architect C 8000 System (Abbott
Laboratories, Abbott Park, IL, USA).2.6. Statistical analysisAll the data are expressed as mean ± standard deviation.
Statistical analyses were performed using SPSS version 16.0
(SPSS Inc., Chicago, IL, USA). To compare the ratio of cat-
egorical variables, we used the Chi-square test [sex (female/
male) and smoking status]. Normality of the variables was
evaluated using the one-sample KolmogoroveSmirnov test.
Normal distributions of variables were examined using the
independent samples t test, and non-normally distributed
variables were examined using the ManneWhitney U test.
Groups of data were compared with an analysis of variance
followed by Tukey's multiple comparison tests. A multivariate
analysis was used to compare mean levels of serum TAS, TOS,
IMA, and ox-LDL concentrations between patients with
GOLD Stages II, III, and IV and control participants. Differ-
ences were considered significant at a probability level of
p < 0.05.
Table 2
Serum and plasma biomarkers of patients and control individuals.
Control
individuals
n ¼ 45
Stable COPD
patients
n ¼ 51
p
IMA (ABSU) 0.62 ± 0.26 0.98 ± 0.25 0.001
Adjusted IMA (ABSU) 0.62 ± 0.25 0.94 ± 0.31 0.001
TOS (mmol H2O2 equiv./L) 4.53 ± 3.81 6.51 ± 4.85 0.042
TAS (mmol Trolox equiv./L) 1.53 ± 0.14 1.59 ± 0.20 0.132
Ox-LDL (mU/L) 4.51 ± 2.05 5.91 ± 3.61 0.034
Triglycerides (mg/dL) 124.62 ± 46.32 133.39 ± 47.22 0.429
Total-C (mg/dL) 192.64 ± 33.82 181.50 ± 39.72 0.197
HDL-C (mg/dL) 44.19 ± 10.14 36.49 ± 9.60 0.001
LDL-C (mg/dL) 121.34 ± 29.43 115.16 ± 32.86 0.398
All values are mean ± standard deviation.
ABSU ¼ absorbance units; COPD ¼ chronic obstructive pulmonary disease;
equiv. ¼ equivalent; HDL-C ¼ high-density lipoprotein cholesterol;
IMA ¼ ischemia modified albumin; LDL-C ¼ low-density lipoprotein
cholesterol; Ox-LDL ¼ oxidized low-density lipoprotein; TAS ¼ total anti-
oxidant status; TOS ¼ total oxidant status; Total-C ¼ total cholesterol.
705U. Can et al. / Journal of the Chinese Medical Association 78 (2015) 702e7083. Results
Fifty-one (32 smokers and 19 nonsmokers) stable COPD
patients and 45 (25 smokers and 20 nonsmokers) healthy
control individuals were studied. Clinical and demographic
characteristics of COPD patients and healthy individuals are
presented in Table 1. Smoking history, smoking status, age,
sex, and BMI were similar between groups.
Biochemical parameter levels in COPD patients with
GOLD stages and the controls are shown in Table 3. Serum
IMA levels of COPD patients were significantly higher than
those of the control participants ( p ¼ 0.001). Patients with
GOLD Stages II, III, and IV had significantly higher IMA
levels than those of control individuals ( p ¼ 0.004, p ¼ 0.001,
and p ¼ 0.001, respectively) (Table 3). There was a significant
difference of serum IMA levels between GOLD Stages II, III,
and IV in patients ( p ¼ 0.001) (Table 3). Serum TOS levels of
patients with COPD were significantly higher than those of
control individuals ( p ¼ 0.042) (Table 2). Patients with GOLD
Stage IV had significantly higher serum TOS levels, compared
with those of control individuals ( p ¼ 0.042) (Table 3). A
significant difference of serum TOS levels was also detected
between GOLD Stages II, III, and IV in patients ( p ¼ 0.045)
(Table 3).
There was no difference between serum TAS levels of
COPD patients and control individuals ( p ¼ 0.137) (Table 2).
Serum ox-LDL levels of COPD patients were significantly
higher than those of control participants ( p ¼ 0.034) (Table 2).
Patients with GOLD Stage IV had significantly higher ox-LDL
levels than those of control individuals ( p ¼ 0.033) (Table 3).
There was no difference between serum triglycerides, total-C,
and LDL-C levels of COPD patients and control individualsTable 1
Clinical and demographic characteristics of patient and control groups.
Control
individuals
n ¼ 45
Stable COPD
patients
n ¼ 51
p
Age (y) 54.8 ± 3.8 56.92 ± 3.0 0.084
Sex (male/female) 32/13 42/9 0.144
BMI (kg/m2) 27.53 ± 3.4 28.76 ± 2.9 0.082
Disease duration (y) d 14.88 ± 9.0
Smoking history
(pack-year)
37.85 ± 11.56 38.45 ± 17.14 0.852
Smoking status
(smoker/nonsmoker)
25/20 32/19 0.220
FEV1 (%) 94.1 ± 2.3 43.97 ± 16.8 0.001
FEV1/FVC (%) 85 ± 0.8 61.73 ± 9.5 0.001
Arterial pO2 (mmHg) 92.4 ± 1.2 64.25 ± 15.3 0.001
Arterial pCO2 (mmHg) 41.3 ± 0.6 44.14 ± 8.8 0.001
GOLD Stage II n ¼ 19
GOLD Stage III n ¼ 17
GOLD Stage IV n ¼ 15
All values (except GOLD stage, sex and smoking status) are mean ± standard
deviations.
BMI ¼ body mass index; COPD ¼ chronic obstructive pulmonary disease;
FEV1 ¼ forced expiratory volume in 1 second; FVC ¼ forced vital capacity;
GOLD ¼ Global Initiative for Chronic Obstructive Lung Disease.( p ¼ 0.429, p ¼ 0.197, and p ¼ 0.398, respectively) (Table 2).
Serum HDL-C levels of COPD patients were significantly
lower, compared with those of control individuals ( p ¼ 0.001)
(Table 2). Patients with GOLD Stages III and IV had signifi-
cantly lower HDL-C levels than control individuals
( p ¼ 0.040 and p ¼ 0.035, respectively) (Table 3). There was a
significant difference between serum HDL-C levels of patients
with GOLD Stages II, III, and IV ( p ¼ 0.010) (Table 3). No
difference was observed between serum ox-LDL, TAS, serum
triglycerides, total-C, and LDL-C levels of patients with
GOLD Stages II, III, and IV ( p ¼ 0.053, p ¼ 0.137, p ¼ 0.789,
p ¼ 0.437, and p ¼ 0.758, respectively) (Table 3).
In multivariate analysis, when comparing patients with
GOLD Stages II, III, and IV with control individuals, a sig-
nificant difference was found with respect to IMA levels
( p ¼ 0.001, p ¼ 0.001, and p ¼ 0.001, respectively). Patients
with GOLD Stages II, III, and IV showed a significant dif-
ference with respect to ox-LDL levels, compared to control
individuals ( p ¼ 0.516, p ¼ 0.165, and p ¼ 0.002, respec-
tively). Given TAS and TOS levels in patients with GOLD
Stages II, III, and IV, we also found a significant difference
from those of the control individuals ( p ¼ 0.224, p ¼ 0.119,
and p ¼ 0.040; and p ¼ 0.283, p ¼ 0.807, and p ¼ 0.008,
respectively).
4. Discussion
Serum IMA, ox-LDL, and TOS levels were found to be
elevated in patients with COPD, compared to control in-
dividuals. Serum IMA levels were significantly increased in
patients with GOLD Stages II, III, and IV, compared with
those of control individuals, while levels of ox-LDL and TOS
were significantly increased in patients with GOLD Stage IV
compared to control individuals. Additionally, a significant
difference was found between serum IMA, TOS, and HDL-C
levels detected in GOLD Stages II, III, and IV. To the best of
our knowledge, this is the first study to examine the
Table 3
Serum and plasma biomarkers in GOLD stages of patients and control individuals.
Control group
n ¼ 45
COPD patients
GOLD Stage II
n ¼ 19
COPD patients
GOLD Stage III
n ¼ 17
COPD patients
GOLD Stage IV
n ¼ 15
p
IMA 0.62 ± 0.3 0.94 ± 0.4* 0.96 ± 0.2*** 1.01 ± 0.2*** 0.001
TOS 4.53 ± 3.8 4.99 ± 2.3 6.49 ± 4.8 8.48 ± 6.4** 0.045
TAS 1.53 ± 0.1 1.62 ± 0.3 1.62 ± 0.2 1.64 ± 0.2 0.137
Ox-LDL 4.51 ± 2.0 4.99 ± 3.0 5.57 ± 3.0 6.91 ± 4.4**** 0.053
Triglycerides 124.62 ± 46.3 139.46 ± 45.4 133.00 ± 43.0 126.73 ± 57.3 0.789
Total-C 192.64 ± 33.8 178.69 ± 42.5 189.50 ± 32.9 174.64 ± 45.9 0.437
HDL-C 44.19 ± 10.1 38.55 ± 11.6 35.84 ± 8.9****** 35.45 ± 9.0***** 0.010
LDL-C 121.34 ± 29.4 114.86 ± 30.8 119.16 ± 33.1 110.42 ± 37.2 0.758
All values are mean ± standard deviation.
*p ¼ 0.004, compared with control group for IMA.
**p ¼ 0.042, compared with control group for TOS.
***p ¼ 0.001, compared with control group for IMA.
****p ¼ 0.033, compared with control group for Ox-LDL.
*****p ¼ 0.035, compared with control group for HDL-C.
******p ¼ 0.040, compared with control group for HDL-C.
COPD ¼ chronic obstructive pulmonary disease; GOLD ¼ Global Initiative for Chronic Obstructive Lung Disease; HDL-C ¼ high-density lipoprotein cholesterol;
IMA ¼ ischemia modified albumin; LDL-C ¼ low-density lipoprotein cholesterol; Ox-LDL ¼ oxidized low-density lipoprotein; TAS ¼ total antioxidant status;
TOS ¼ total oxidant status; Total-C ¼ total cholesterol.
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indicators of lung function, inflammation, and oxidative stress.
Serum albumin is a major antioxidant for the respiratory
tract19 because the N-terminal region of albumin eliminates
free oxygen radicals and binds transition metals such as cobalt,
copper, and nickel.20 The elevation of IMA is directly asso-
ciated with free radicals generated during ischemia.20 IMA
levels are elevated in cardiac ischemia, cerebrovascular oc-
clusion, pulmonary ischemia, gastrointestinal ischemia, and
muscle ischemia.8,19,20
Hypoxia was demonstrated to impair endothelium-
dependent pulmonary artery relaxation in patients with se-
vere COPD.19 Chawla et al21 reported that IMA was signifi-
cantly elevated in cardiac ischemia patients, compared with
that in control individuals. IMA demonstrates a good
discrimination between ischemic and nonischemic patients.
Our results showed that serum IMA levels of COPD patients
were significantly higher than those of control individuals.
Systemic levels of IMA are increased positively in patients
with GOLD Stages II, III, and IV, compared with control in-
dividuals. This finding shows that IMA is a useful marker for
hypoxia and oxidative stress in COPD. Our findings are
consistent with those of Turedi et al,22 demonstrating that
serum IMA levels were significantly higher in patients expe-
riencing pulmonary embolism, compared with those in healthy
individuals. In another study, Hackett et al19 found that
parenchymal tissue from COPD patients who were current
smokers contained lower levels of total human serum albumin,
but higher levels of carbonylated and oxidized human serum
albumin, compared with patients with normal lung function.
Based on our findings consistent with those of these studies,
we speculate that IMA increases under the conditions of free
radical production and hypoxia, such as COPD.
Oxidized LDL activates several transcription factors, and
increases the chemotaxis of neutrophils and monocytes,secretion of chemokines and cytokines, and intracellular ROS
production involved in the pathogenesis of COPD.23 In our
study, serum ox-LDL levels of COPD patients were signifi-
cantly higher than those of control participants, and ox-LDL
was increased, especially in patients with GOLD Stage IV.
Shen et al23 suggested that serum ox-LDL levels are increased
in COPD patients, and that these levels are associated with
lung function, inflammation, and oxidative stress in COPD.
Cigarette smoking is the main pathological factor for COPD.24
Yamaguchi et al24 found that smokers demonstrated a signif-
icantly higher level of thiobarbituric acid-reactive substances
and 8-hydroxydeoxyguanosine, as well as a significantly lower
level of vitamin E than nonsmoker individuals. A subfraction
assay of LDL showed an increase in oxidatively modified
LDL, as expressed by lower levels of LDL-1 and higher levels
of LDL-2. The results reported in these studies are also
consistent with our results.
An imbalance between oxidative stress and antioxidative
capacity plays an important role in the development and
progression of COPD. We found that serum TOS levels of
COPD patients were significantly higher than those of control
individuals. Santos et al25 found that the plasma concentration
of protein carbonyls was significantly increased in COPD
patients compared to that in control individuals. The activity
of antioxidant enzyme superoxide dismutase was increased in
erythrocytes, while glutathione peroxidase activity was
decreased in total blood. Levels of selenium in plasma were
also found to be lower in COPD patients, compared with those
in control individuals. In a study by Nadeem et al,26 it was
found that red cell antioxidative enzyme activities were altered
with lower activity of glutathione peroxidase, greater activity
of superoxide dismutase, and similar activity of catalase in
patients with COPD, compared with control individuals.
Ferric-reducing antioxidant power of plasma was lower in
patients, compared with that in control individuals, although
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et al,27 a marker of oxidative stress, malondialdehyde, which is
a lipid peroxidation-derived product, was found to be signifi-
cantly higher in COPD patients, when compared with control
participants. COPD patients had a significant decrease in
antioxidant status, compared with the control group. Lin et al28
determined that compared with healthy control individuals,
COPD patients had significantly lower plasma concentrations
of vitamins A, C, and E, alpha-and beta-carotene, and total
carotenoids, but significantly higher H2O2-induced DNA
damage in white blood cells.
It is well understood that antioxidants are altered in
COPD. Some studies demonstrated a marked decrease in
plasma antioxidant capacity, while other studies showed
essentially opposite findings. We found no difference be-
tween serum TAS levels of COPD patients and control par-
ticipants. A mucolytic drug such as NAC is prescribed for
some COPD patients over long periods of time. NAC has a
direct antioxidant property because of interaction between its
thiol and ROS, and an indirect antioxidant property due to its
role as a glutathione precursor. Treatment with NAC in
humans changes the pulmonary oxidanteantioxidant imbal-
ance.29 Sadowska et al30 showed that long-term oral admin-
istration of NAC reduces H2O2 formation in the airways of
COPD patients and that there is evidence of antioxidant ac-
tion of the drug.
In light of our results, no difference was found between
serum triglycerides, total-C, and LDL-C levels of COPD pa-
tients and control individuals. Serum HDL-C levels of COPD
patients were significantly lower than the corresponding levels
of control individuals. Lowering of HDL-C levels may in-
crease the risk of coronary disease. Basili et al31 reported that
total-C, HDL-C, LDL-C, and triglycerides showed similar
levels between COPD patients and control individuals. How-
ever, an insufficient number of studies related to atherogenetic
lipid pattern in COPD have been conducted. Therefore, addi-
tional studies are necessary to further elucidate the role of
lipids in COPD cases.
In conclusion, our study showed that serum oxidative stress
parameters such as IMA, ox-LDL, and TOS are elevated in
patients with stable COPD. We consider that IMA, ox-LDL,
and TOS may be increased as a result of chronic hypoxia,
inflammation, and oxidative stress in patients with severe and
very severe stable COPD and that antioxidants, which may
repair the impaired oxidanteantioxidant balance in COPD, are
needed to prevent the development of COPD.
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